Kirovs Lipmans

Latvian pharmaceutical manufacturing company Grindeks opens new subsidiaries worldwide

Retrieved on: 
Wednesday, April 3, 2024
Central nervous system, Growth, Oncology, Patient, Diabetes, Council, Investment, Kirovs Lipmans, Pharmaceutical industry

To expand its export markets, Grindeks has established 28 subsidiaries in Europe and other countries around the world, including Canada and the United States.

Key Points: 
  • To expand its export markets, Grindeks has established 28 subsidiaries in Europe and other countries around the world, including Canada and the United States.
  • Already in 2022, Grindeks began diversifying its export markets by opening 28 subsidiaries in various countries, gradually commencing operations.
  • Development of modern medicines – 30 new products, over 100 pharmaceutical formulations under development
    To meet the growing demand for Grindeks medicines worldwide, the company actively works on developing new products.
  • Chairman of the Council of Grindeks, Kirovs Lipmans: "The foundation of Grindeks' successful operations lies in international cooperation, continuous growth, and product exports worldwide.

Latvian pharmaceutical manufacturing company Grindeks opens new subsidiaries worldwide

Retrieved on: 
Wednesday, April 3, 2024
Central nervous system, Growth, Oncology, Patient, Diabetes, Council, Investment, Kirovs Lipmans, Pharmaceutical industry

To expand its export markets, Grindeks has established 28 subsidiaries in Europe and other countries around the world, including Canada and the United States.

Key Points: 
  • To expand its export markets, Grindeks has established 28 subsidiaries in Europe and other countries around the world, including Canada and the United States.
  • Already in 2022, Grindeks began diversifying its export markets by opening 28 subsidiaries in various countries, gradually commencing operations.
  • Development of modern medicines – 30 new products, over 100 pharmaceutical formulations under development
    To meet the growing demand for Grindeks medicines worldwide, the company actively works on developing new products.
  • Chairman of the Council of Grindeks, Kirovs Lipmans: "The foundation of Grindeks' successful operations lies in international cooperation, continuous growth, and product exports worldwide.

"Grindeks" Celebrates 75-year Anniversary

Retrieved on: 
Tuesday, December 21, 2021
Online, Reading, Science, Latvian Academy of Sciences, JSC, Environment, Hospital, Molecular biology, Time, Board, HBM, Grindelia, Diabetes, Experiment, Hormone, Investment, Council, Electricity, Food, Vitamin, Meldonium, Microbiology, Solution, Tablet, Internal, Ministry, Degenerative disease, Invention, Laboratory, Chemistry, Grindeks, TOP, Kirovs Lipmans, Group, Patient, Growth, Fine chemical, Pharmaceutical industry, Baltic states, Baltic

RIGA, Latvia, Dec. 21, 2021 /PRNewswire/ -- Today on December 21, JSC "Grindeks", the leading pharmaceutical manufacturer in the Baltic States celebrates its 75-year anniversary.

Key Points: 
  • RIGA, Latvia, Dec. 21, 2021 /PRNewswire/ -- Today on December 21, JSC "Grindeks", the leading pharmaceutical manufacturer in the Baltic States celebrates its 75-year anniversary.
  • Each one of them is contributing to the growth of the Group and being an integral part of the corporation.
  • "Grindeks" celebrated its anniversary throughout 2021, organising and supporting conferences and various projects that promoted cooperation between health professionals and the pharmaceutical company.
  • In honour of its 75-year anniversary, "Grindeks" created a book for families that was delivered to 18 hospitals in Latvia, with a total of 15 000 copies.

"Grindeks" Celebrates 75-year Anniversary

Retrieved on: 
Tuesday, December 21, 2021
Online, Reading, Science, Latvian Academy of Sciences, JSC, Environment, Hospital, Molecular biology, Time, Board, HBM, Grindelia, Diabetes, Experiment, Hormone, Investment, Council, Electricity, Food, Vitamin, Meldonium, Microbiology, Solution, Tablet, Internal, Ministry, Degenerative disease, Invention, Laboratory, Chemistry, Grindeks, TOP, Kirovs Lipmans, Group, Patient, Growth, Fine chemical, Pharmaceutical industry, Baltic states, Baltic

RIGA, Latvia, Dec. 21, 2021 /PRNewswire/ -- Today on December 21, JSC "Grindeks", the leading pharmaceutical manufacturer in the Baltic States celebrates its 75-year anniversary.

Key Points: 
  • RIGA, Latvia, Dec. 21, 2021 /PRNewswire/ -- Today on December 21, JSC "Grindeks", the leading pharmaceutical manufacturer in the Baltic States celebrates its 75-year anniversary.
  • Each one of them is contributing to the growth of the Group and being an integral part of the corporation.
  • "Grindeks" celebrated its anniversary throughout 2021, organising and supporting conferences and various projects that promoted cooperation between health professionals and the pharmaceutical company.
  • In honour of its 75-year anniversary, "Grindeks" created a book for families that was delivered to 18 hospitals in Latvia, with a total of 15 000 copies.

"Grindeks" Group has reached record high turnover and profit in the first nine months of 2021

Retrieved on: 
Monday, November 8, 2021
Emirates, CIS, European Union, JSC, Kirovs Lipmans, Union, Growth, Investment, Goal, Research, LLC, Sale, Board, Thought, HBM, Council, Tegafur, Diabetes, Central nervous system, Patient, United Arab Emirates, Animal, Motor vehicle, Pharmaceutical industry, Fine chemical

RIGA, Latvia, Nov. 8, 2021 /PRNewswire/ -- The consolidated, provisional financial data of "Grindeks" Group shows that in the first nine months of 2021 the Group has reached record high turnover and profit. In this period the turnover of "Grindeks" Group reached 168.9 million euros, which is 31.8 million euros or 23% more than in the first nine months of 2020. The profit of the Group in the first nine months of 2021 amounted to 27.6 million euros which is 15.5 million euros or twice as much as in the first nine months of 2020.

Key Points: 
  • RIGA, Latvia, Nov. 8, 2021 /PRNewswire/ -- The consolidated, provisional financial data of "Grindeks" Group shows that in the first nine months of 2021 the Group has reached record high turnover and profit.
  • In this period the turnover of "Grindeks" Group reached 168.9 million euros, which is 31.8 million euros or 23% more than in the first nine months of 2020.
  • "Grindeks" Group's record high profit and turnover in the first nine months has been achieved due to a significant increase in demand for cardiovascular and central nervous system products.
  • During the first nine months of 2021, the Group exported its production to 97 countries for a total amount of 160 million euros.

"Grindeks" Group has reached record high turnover and profit in the first nine months of 2021

Retrieved on: 
Monday, November 8, 2021
Emirates, CIS, European Union, JSC, Kirovs Lipmans, Union, Growth, Investment, Goal, Research, LLC, Sale, Board, Thought, HBM, Council, Tegafur, Diabetes, Central nervous system, Patient, United Arab Emirates, Animal, Motor vehicle, Pharmaceutical industry, Fine chemical

RIGA, Latvia, Nov. 8, 2021 /PRNewswire/ -- The consolidated, provisional financial data of "Grindeks" Group shows that in the first nine months of 2021 the Group has reached record high turnover and profit.

Key Points: 
  • RIGA, Latvia, Nov. 8, 2021 /PRNewswire/ -- The consolidated, provisional financial data of "Grindeks" Group shows that in the first nine months of 2021 the Group has reached record high turnover and profit.
  • In this period the turnover of "Grindeks" Group reached 168.9 million euros, which is 31.8 million euros or 23% more than in the first nine months of 2020.
  • "Grindeks" Group's record high profit and turnover in the first nine months has been achieved due to a significant increase in demand for cardiovascular and central nervous system products.
  • During the first nine months of 2021, the Group exported its production to 97 countries for a total amount of 160 million euros.